Prospective Phase ll trial of Erlotinib for Advanced Non Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations

Phase 2

• Conditions: on-small cell Lung Cancer

• Registration Number: JPRN-UMIN000002880
• Lead Sponsor: Federation of National Public Service Personnel Mutual Aid Associations TORANOMON HOSPITAL Department of Respiratory Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-12-11
• Study Completion: 2014-06-12
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis,or drug-induced pneumonitis 2)Patients with massive pleural or pericardial effusion ,or ascites 3)Patients with active severe infections 4)Cases with past history of administration of HER related agents 5)Impossible cases with oral administration 6)Patients with active opthalmological disease 7) Patients with active concomitant malignancy 8) Patients with symptomatic brain metastasis 9)Patients with double cancer 10)Patients with uncontrollabe diabetes mellitus 11)Patients with uncontrollable complications 12)Inappropriate patients for this study judged by the physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified